Skip to search formSkip to main contentSkip to account menu

indacaterol

Known as: 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one 
National Institutes of Health

Related topics

Related topics

10 relations
Adrenergic beta2-Agonists [MoA]Glycopyrrolate 0.0156 MG / indacaterol 0.0275 MG Inhalant Powder [Utibron]indacaterol 0.075 MG Inhalant Powderindacaterol 0.075 MG Inhalant Powder [Arcapta]

Broader (2)

IndansQuinolones

Narrower (4)

OnbrezQAB-149arcapta neohalerindacaterol maleate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Indacaterol/Glycopyrronium improves pulmonary ventilation and ventilation inhomogeneity in the CLAIM Study
Background: Ventilation of the lungs is disturbed in COPD. Bronchodilator treatment reduces airway obstruction and improves… 
Review
2018
Review
2018
[Current position of new fixed-dose combination of tiotropium and olodaterol - its role in the treatment of chronic obstructive pulmonary disease in the Czech Republic].
COPD is a serious pulmonary disease with rising global socioeconomic impact. From the perspective of the Czech Republic COPD was… 
2015
2015
EFFICACY OF INDACATEROL, A MODERN ULTRALONG-ACTING BRONCHODILATOR, IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Chronic obstructive pulmonary disease (COPD) is one of the most prevalent chronic diseases among elderly population worldwide… 
2012
2012
▼ Indacaterol for COPD
▼Indacaterol powder for inhalation (Onbrez Breezhaler – Novartis) is a long-acting beta2 agonist, licensed for once-daily use as… 
2012
2012
Its use as imidazo [4,5-c] quinolin-2-one compounds and PI3 kinase / mTOR dual inhibitors
The present invention inhibit both PI3K and mTOR, providing thereby useful in the treatment of cancer, imidazo [4,5-c] quinolin-2… 
2011
2011
Role of indacaterol in the management of asthma and chronic obstructive pulmonary disease
Indacaterol is the first of a new category of inhaled β2-agonists with a very long duration of action that allows for once-daily… 
Review
2011
Review
2011
Indacaterol. A long-acting beta-2 agonist, no advantages in COPD.
  • Prescrire international
  • 2011
  • Corpus ID: 20925599
In patients with chronic obstructive pulmonary disease (COPD), bronchodilator drugs have only modest symptomatic efficacy. There… 
2011
2011
Lack of effect of mild and moderate hepatic impairment or UGT1A1 genotype on the pharmacokinetics of inhaled indacaterol
Introduction and aim: Indacaterol (IND) is an inhaled long acting beta2 agonist for once-daily treatment of COPD. IND is highly… 
2009
2009
ONCE-DAILY INDACATEROL PROVIDES EFFECTIVE 24-HOUR BRONCHODILATION IN COPD: A DOUBLE-BLIND COMPARISON WITH TIOTROPIUM
2001
2001
Reaction Of 8-(1-Hydroxy Ethyl) 3,4,5,6,7,8 Hexahydro-[1h]- Quinolin-2-One With Benzaldehy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)